The Hypertension in the Very Elderly Trial (HYVET)

SummaryThe Hypertension in the Very Elderly Trial (HYVET) is a multicentre, open, randomised, controlled trial. The aim of this trial is to investigate the effect of active treatment on stroke incidence in hypertensive patients over the age of 80 years. Secondary end-points include total cardiovascular mortality and morbidity.Entry criteria include a sustained sitting systolic blood pressure of 160 to 219mm Hg plus a sustained sitting diastolic pressure of 95 to 109mm Hg. Also required is a standing systolic blood pressure of at least 140mm Hg. Patients must give their informed consent, and be free of congestive heart failure requiring treatment, gout, renal failure or a recent cerebral haemorrhage. Patients are to be randomised to 3 groups — (i) no treatment; (ii) treatment with a diuretic [bendroflumethiazide (bendrofluazide)]; or (iii) treatment with an angiotensin converting enzyme (ACE) inhibitor (lisinopril).Starting dosage for bendroflumethiazide and lisinopril is 2.5 mg/day. In order to achieve goal sitting systolic and diastolic blood pressures (< 150/80mm Hg), a doubling of the dosage is allowed. Furthermore, slow release diltiazem (120 mg/day increasing to 240 mg/day if required) may be added to the medication of the actively treated groups. These drugs have been chosen as inexpensive and appropriate representatives of their therapeutic classes.700 patients in each group (a total of 2100) will be sufficient to detect a 40% difference in cerebrovascular events between no treatment and active treatment (α = 0.01, 1−β = 0.90). These numbers will also detect a difference in total mortality of 25% and in cardiovascular mortality of 35%.The pilot phase of the trial has been started with support from the British Heart Foundation. Centres which are interested in taking part should contact C. J. Bulpitt or any of the other authors.

[1]  E. Agner,et al.  Natural history of angina pectoris, possible previous myocardial infarction and intermittent claudication during the eighth decade. A longitudinal epidemiologic study. , 2009, Acta medica Scandinavica.

[2]  C. Bulpitt,et al.  Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial , 2008, The Lancet Neurology.

[3]  C. Bulpitt,et al.  Prognostic Significance of Blood Pressure in the Very Old , 1994, Drugs & aging.

[4]  B. Dahlöf.  Drug treatment of hypertension. , 1993, The Netherlands journal of medicine.

[5]  C. Bulpitt.  A risk-benefit analysis for the treatment of hypertension. , 1993, Postgraduate medical journal.

[6]  C. Bulpitt,et al.  Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. , 1993, BMJ.

[7]  C. Bulpitt,et al.  Aging, blood pressure and mortality. , 1992, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[8]  C. Moysés,et al.  Safety of long-term use of lisinopril for congestive heart failure. , 1992, The American journal of cardiology.

[9]  J. Emeriau.  What is the Clinical Relevance of Isolated Systolic Hypertension? , 1992, Drugs & aging.

[10]  B. Dahlöf,et al.  Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) , 1991, The Lancet.

[11]  J. Webster,et al.  Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization , 1991, Aging.

[12]  O. Tresznewsky,et al.  Once‐Daily Lisinopril Compared with Twice‐Daily Captopril in the Treatment of Mild to Moderate Hypertension: Assessment of Office and Ambulatory Blood Pressures , 1990, Journal of clinical pharmacology.

[13]  M. Brodie,et al.  Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. , 1990, BMJ.

[14]  P. Vandepapelière,et al.  Safety and efficacy of lisinopril in elderly patients with mild to moderate hypertension. , 1989, Journal of human hypertension.

[15]  D. Herpin,et al.  Assessment of the antihypertensive effect of lisinopril using 24-hour ambulatory monitoring. , 1989, Journal of human hypertension.

[16]  T G Ganiats,et al.  Paradoxical survival of elderly men with high blood pressure. , 1989, BMJ.

[17]  P. Waller,et al.  DILTIAZEM AND HEART BLOCK , 1989, The Lancet.

[18]  W. Klinke,et al.  A randomized double-blind comparison of diltiazem and nifedipine in stable angina. , 1988, Journal of the American College of Cardiology.

[19]  W. Kannel,et al.  Proportional Hazards Analysis of Risk Factors for Coronary Heart Disease in Individuals Aged 65 or Older , 1988, Journal of the American Geriatrics Society.

[20]  S. Sheps,et al.  Antihypertensive efficacy of lisinopril. Ambulatory blood pressure monitoring. , 1988, American journal of hypertension.

[21]  Matti Haavisto,et al.  Blood pressure and five year survival in the very old , 1988, British medical journal.

[22]  J. Reid,et al.  Lisinopril and nifedipine: no acute interaction in normotensives. , 1988, British journal of clinical pharmacology.

[23]  J. G. Evans.  Blood pressure and stroke in an elderly English population. , 1987, Journal of epidemiology and community health.

[24]  J. Hill,et al.  Comparison of diltiazem and nifedipine alone and in combination in patients with coronary artery spasm. , 1987, Journal of the American College of Cardiology.

[25]  T S Warrender,et al.  Randomised trial of treatment of hypertension in elderly patients in primary care. , 1986, British medical journal.

[26]  I. Starkey,et al.  Recommendations on blood pressure measurement. , 1986, British medical journal.

[27]  C. Bulpitt,et al.  EFFICACY OF ANTIHYPERTENSIVE DRUG TREATMENT ACCORDING TO AGE, SEX, BLOOD PRESSURE, AND PREVIOUS CARDIOVASCULAR DISEASE IN PATIENTS OVER THE AGE OF 60 , 1986, The Lancet.

[28]  C. Bulpitt,et al.  Mortality and Morbidity Results from the European Working Party on High Blood Pressure in the Elderly Trial , 1985, The Lancet.

[29]  W. Meyer-Sabellek,et al.  1 Long-term Treatment with Diltiazem and Nifedipine in Essential Hypertension , 1984 .

[30]  T. Nakano,et al.  Effects of diltiazem on cardiovascular responses during exercise in systemic hypertension and comparison with propranolol. , 1983, The American journal of cardiology.

[31]  E. Barrett-Connor,et al.  Isolated systolic hypertension and mortality after age 60 years. A prospective population-based study. , 1983, American journal of epidemiology.

[32]  E. Pritchett,et al.  Pharmacokinetic and pharmacodynamic effects of diltiazem. , 1983, The American journal of cardiology.

[33]  R. O'rourke,et al.  Differential effects of systemic and intracoronary calcium channel blocking agents on global and regional left ventricular function in conscious dogs. , 1981, American heart journal.

[34]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[35]  S. Pocock.  Group sequential methods in the design and analysis of clinical trials , 1977 .

[36]  H. Barnett,et al.  Cerebral Ischemia : The Role of Thrombosis and of Antithrombotic Therapy Study Group on Antithrombotic Therapy , 2005 .

[37]  S. Chinn,et al.  Screening for Hypertension: Some Epidemiological Observations , 1974, British medical journal.

[38]  R. Shekelle,et al.  Hypertension and Risk of Stroke in an Elderly Population , 1974, Stroke.

[39]  H. Hodkinson.  Evaluation of a mental test score for assessment of mental impairment in the elderly. , 1972, Age and ageing.

[40]  H. Tufo,et al.  Epidemiology of stroke in elderly persons. , 1970, Neurology.

[41]  J. Staessen,et al.  Review of the major hypertension trials in the elderly , 2004, Cardiovascular Drugs and Therapy.

[42]  J. Kostis,et al.  Twenty-four hour blood pressure effect of once-daily lisinopril, enalapril, and placebo in patients with mild to moderate hypertension. , 1992, Journal of human hypertension.

[43]  K. Pennert,et al.  Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. , 1992, American journal of hypertension.

[44]  N. Murray.  Duration of angiotensin-converting enzyme inhibition: implications for tolerability. , 1991, Cardiology.

[45]  L. Hansson,et al.  Calcium antagonists in the treatment of hypertension: state of the art. , 1990, Journal of cardiovascular pharmacology.

[46]  S. Chrysant,et al.  Antihypertensive effectiveness of lisinopril and metoprolol alone and in combination with other drugs , 1989 .

[47]  D. Natin,et al.  Lisinopril in Elderly Patients with Hypertension , 1987, Journal of cardiovascular pharmacology.

[48]  J. Mehta,et al.  Controlled Multicenter Study of the Antihypertensive Effects of Lisinopril, Hydrochlorothiazide, and Lisinopril plus Hydrochlorothiazide in the Treatment of 394 Patients with Mild to Moderate Essential Hypertension , 1987, Journal of cardiovascular pharmacology.

[49]  G. D. Johnston,et al.  Comparative Trial of Lisinopril and Nifedipine in Mild to Severe Essential Hypertension , 1987, Journal of cardiovascular pharmacology.

[50]  W. G. Reed,et al.  The Antihypertensive Effect of Lisinopril Compared to Atenolol in Patients with Mild to Moderate Hypertension , 1987, Journal of Cardiovascular Pharmacology.

[51]  K. Aho,et al.  Cerebrovascular disease in the community: results of a WHO collaborative study. , 1980, Bulletin of the World Health Organization.

[52]  A. Ostfeld,et al.  XI. Transient Focal Cerebral Ischemia: Epidemiological and Clinical Aspects BY THE STUDY GROUP ON TIA CRITERIA AND DETECTION , 1974 .